2009
DOI: 10.1179/csm.2009.3.4.357
|View full text |Cite
|
Sign up to set email alerts
|

Home healthcare: Emerging evidence for NHS commissioners

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2011
2011
2020
2020

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 3 publications
0
3
0
Order By: Relevance
“… 18 In the UK and the US, the excessive burden on some chemotherapy units has led to the development of an innovative concept of care model which would allow less complex cancer treatments to be delivered at home outside of the acute hospital setting. 19 For instance the Christie NHS Foundation Trust in the UK has rapidly implemented the home delivery of trastuzumab to early-stage HER2-positive breast cancer patients after the first three hospital administrations in the absence of significant side effects. All treatment is carried out under the direction of the patient’s oncologist, who retains ultimate responsibility for the patient’s care and with whom close contact is maintained at all times.…”
Section: Clinical Evidencementioning
confidence: 99%
“… 18 In the UK and the US, the excessive burden on some chemotherapy units has led to the development of an innovative concept of care model which would allow less complex cancer treatments to be delivered at home outside of the acute hospital setting. 19 For instance the Christie NHS Foundation Trust in the UK has rapidly implemented the home delivery of trastuzumab to early-stage HER2-positive breast cancer patients after the first three hospital administrations in the absence of significant side effects. All treatment is carried out under the direction of the patient’s oncologist, who retains ultimate responsibility for the patient’s care and with whom close contact is maintained at all times.…”
Section: Clinical Evidencementioning
confidence: 99%
“…Reviews of the literature published in 2004 and 2005 report mixed cost outcomes (Boothroyd & Lehoux ; Hirtzlin & Preaubert‐Hayes ). Although home‐based chemotherapy is generally less costly than inpatient hospital treatment, it may not be less costly than outpatient treatment (Boothroyd & Lehoux ; O'Neill & Wallis ). However, two more recent randomised controlled trials conducted in the UK have found no differences in cost between hospital, outpatient and home chemotherapy delivery (Hall & Lloyd ; Corrie et al .…”
Section: Resultsmentioning
confidence: 99%
“…Reviewing data from other visitors to the Bus, such as friends and family members, revealed that overall, these visitors are also very happy with the services provided and received on the Bus compared to previous appointments. No patient mentioned the reduction of risk from hospital acquired infections, which is often cited as a positive aspect of home chemotherapy (O'Neill & Wallis 2009). Nor was it mentioned that on the Bus there is perhaps less contact and support from other patients as in a hospital ward.…”
Section: Discussionmentioning
confidence: 99%